The good news: cramping typically subsides as your body adapts to the medication and reaches a new equilibrium
Savings programs may help lower the cost, but they have limits
H., Bentler, K., Redlinger-Grosse, K., Berry, S
Nissen says its results are likely to steer prescribers and patients toward favoring a dual agonist like tirzepatide
After discontinuing its internal GLP-1 in May of 2025 for causing liver issues, Pfizer won a bidding war against seven other companies for Metsera, which is developing a variety of incretin assets, paying $10 billion in one of 2025s largest M&A deals
Request a consult with our experienced team to learn more about the revolutionary Semaglutide injections for type 2 diabetes and weight loss